MAIA Biotechnology Expands Pivotal Phase 3 THIO-104 Non-Small Cell Lung Cancer Trial into Spain and Portugal
MAIA Biotechnology received regulatory approval from Spain's AEMPS and Portugal's INFARMED to begin screening patients in its pivotal Phase 3 THIO-104 trial of ateganosine in non-small cell lung cancer. The trial has enrolled 65 chemotherapy- and checkpoint-inhibitor-resistant NSCLC patients across 28 European sites and 10 sites in Taiwan, targeting 100 patients dosed by year-end 2026.
Key figures
- Drug Name
- Ateganosine (THIO)
- Phase Of Trial
- Phase 3
- Patients enrolled
- 65
- European countries
- 6
- Interim analysis year
- 2027
- Target patients dosed 2026
- 100
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.